Myriad Genetics Executive Compensation
Myriad Genetics entered into a separation agreement with former Chief Commercial Officer Brian Donnelly following his departure on September 21, 2026. Mr. Donnelly will receive a lump sum severance payment of approximately $1.32 million and accelerated vesting of outstanding time-based and performance-based equity awards for a two-year period. The agreement includes customary non-solicitation and non-disparagement covenants and a release of claims against the company.
- Counterparty
- Brian Donnelly